ALB and neoplasm: To evaluate the in vivo antitumor activity of HuNbTROP2-HSA-MMAE, mice bearing BxPC-3 subcutaneous xenograft tumors were administered different doses (0.2 mg/kg, 1 mg/kg, and 5 mg/kg) of HuNbTROP2-HSA-MMAE or the positive control drug gemcitabine twice a week, and tumor volumes were measured over time.